Anna C Dusenbery
Overview
Explore the profile of Anna C Dusenbery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bulen B, Khazanov N, Hovelson D, Lamb L, Matrana M, Burkard M, et al.
Cancer Res Commun
. 2023 Jul;
3(7):1335-1349.
PMID: 37497337
Significance: This study confirms the utility of the integrative IRS biomarker for predicting anti-PD-L1/PD-1 benefit. IRS significantly improved upon currently available biomarkers, including PD-L1 IHC, TMB, and MSI status. Additional...
2.
Kothari S, Dusenbery A, Doucette A, Zhang D, Ballinger D, Desai A, et al.
Neurooncol Pract
. 2023 Jul;
10(4):370-380.
PMID: 37457221
Background: Recurrent gliomas are therapeutically challenging diseases with few treatment options available. One area of potential therapeutic vulnerability is the presence of targetable oncogenic fusion proteins. Methods: To better understand...
3.
Volaric A, Zadeh S, Dusenbery A, Coppock J, Dibbern M, Jenkins T, et al.
Am J Clin Pathol
. 2021 Apr;
156(3):478-490.
PMID: 33834192
Objectives: Pathology and laboratory medicine (PALM) services in low- and middle-income countries are essential to combat the increasing prevalence of cancer in addition to providing documentation of cancer types and...
4.
Dusenbery A, Maniaci J, Hillerson N, Dill E, Bullock T, Mills A
Am J Surg Pathol
. 2021 Mar;
45(5):701-707.
PMID: 33739790
Suppression of the immune system is intimately linked to the development and progression of malignancy, and immune modulating treatment options have shown promise in a variety of tumor types, including...
5.
Dusenbery A, Davick J, LeGallo R, Williams E
Hum Pathol
. 2020 Aug;
102:88-93.
PMID: 32800346
Spindle cell lipomas/pleomorphic lipomas, mammary-type myofibroblastomas, and cellular angiofibromas are benign mesenchymal tumors that demonstrate histologically overlapping features but with varying anatomic locations and an uncertain etiologic relationship. These tumors...
6.
Coppock J, Dusenbery A, Elghawy O, Fellenstein L, Frierson Jr H, Shildkrot Y
J Am Soc Cytopathol
. 2020 Mar;
9(3):173-176.
PMID: 32113804
Hereditary amyloidosis is a challenging but critical diagnosis, with serious implications with regard to treatment and disease surveillance for both patients and their families. Systemic symptomology is often vague. As...
7.
Mills A, Chinn Z, Rauh L, Dusenbery A, Whitehair R, Saks E, et al.
Int J Gynecol Cancer
. 2019 Mar;
29(3):560-565.
PMID: 30833441
Objective: Although the majority of ovarian granulosa cell tumors can be successfully managed with surgery, a subset require chemotherapy for residual and recurrent disease. The benefit of chemotherapy in this...